Veru reports Q1 revenue $2.1M, cash $40.6M; FDA clears IND for enobosarm with GLP-1 for weight loss

VERU INC.

2024-Q1 EPS reported -$0.08 revenue$2,140,726

Net revenue $2.1M (down from $2.5M YoY); gross profit $1.2M (up from $0.7M).
Cash $40.6M at Dec 31, 2023, bolstered by $35.2M net proceeds from public offering.
FDA cleared IND for enobosarm in combination with GLP-1 drugs to preserve muscle during weight loss.
Phase 2b obesity study to start by April 2024; top-line results expected by end of calendar 2024.
Enobosarm for metastatic breast cancer funding-dependent; sabizabulin COVID program paused without external funding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

VERU INC. reported financial results for fiscal 2024 first quarter ended December 31, 2023.

Period: fiscal 2024 first quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 8, 2024, Veru Inc. issued a press release (the “Press Release”) announcing certain financial highlights for the quarter ended December 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

VERU INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-027504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.